Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is placed sixth connected our database of cheap pharmaceutical stocks.

TheFly reported connected February 10 that Truist Securities expert Les Sulewski raised its terms people connected COLL to $58 from $55 and gave it a Buy rating. The expert emphasized the robustness of the company's wider symptom absorption portfolio and offered a affirmative appraisal of its ongoing momentum with Jornay.

Additionally, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) gave a concern update and its full-year 2026 fiscal outlook successful January. The institution besides highlighted expectations for continuing operational strength. The institution says that it expects nett merchandise gross to scope from $805 cardinal to $825 cardinal for the year. Within that range, Jornay PM is anticipated to nutrient nett income of atleast $190 cardinal to $200 million, which shows its value to the wide enlargement plan. Furthermore, according to COLL, adjusted EBITDA volition scope from $455 cardinal to $475 million, indicating beardown profitability and cautious outgo control. The institution besides has assurance successful the longevity of its portfolio and its quality to prolong net momentum done 2026, arsenic indicated by the updated projection.

Collegium Pharmaceutical, Inc. (NASDQAQ:COLL) is simply a U.S. pharmaceutical institution focused connected processing and commercializing innovative symptom absorption therapies, including abuse-deterrent opioid formulations, leveraging science-based solutions to amended diligent information and attraction outcomes.

While we admit the imaginable of COLL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.